The Quiet Revolution Inside Ozempic: Violence, Vessels, and the Body's Hidden…
GLP-1 medications — semaglutide, tirzepatide, the family of drugs that began as diabetes treatments and became something the world is still learning to describe — are accumulating a second story beneath the first.
The Quiet Revolution Inside Ozempic: Violence, Vessels, and the Body's Hidden Appetite
There is a man I know — I won't say where I met him, somewhere between Singapore and Brussels, the way people in transit exist between coordinates — who told me he'd started Ozempic for his weight and found, almost incidentally, that he'd stopped wanting a drink at the end of a hard day. Not dramatically. Just quietly. The craving had receded like a tide going out, and he hadn't noticed until the shore was empty.
I thought of him when I read the new research.
GLP-1 medications — semaglutide, tirzepatide, the family of drugs that began as diabetes treatments and became something the world is still learning to describe — are accumulating a second story beneath the first. The first story was weight loss, glycaemic control, the before-and-after photographs. The second story is stranger and more interesting. A study published in the Journal of the American Heart Association found that in people with type 2 diabetes and peripheral artery disease — the kind that restricts blood flow to the limbs and carries real amputation risk — GLP-1 medications reduced deaths, amputations, and hospitalisations in ways that went beyond what blood sugar management alone could explain. The vessels themselves, apparently, were responding.
And then there is the behaviour research, which I find the most quietly extraordinary. A study found that GLP-1 users showed measurable reductions in impulsivity, alcohol consumption, and violent behaviour. The mechanism appears to involve the way these drugs interact with dopamine and reward circuitry — the brain's hunger is not only for food, and GLP-1 receptors are distributed in regions that govern craving broadly. Quieting the noise around one appetite, it seems, quiets others.
This is not a reason to romanticise a medication. Every pharmaceutical carries trade-offs, and GLP-1s are no different — the research on altered taste and smell, on gastrointestinal disruption, on what happens when someone stops taking them, remains active and incomplete. But the shape of what's emerging is genuinely new: a drug class that may be touching something deeper than metabolism. Not a magic pill. Something more like a key that opens multiple doors simultaneously, and we're still taking inventory of the rooms.
What this means practically, for anyone on or near a GLP-1, is worth a conversation with whoever is prescribing — not about adding the drug, but about what else might be shifting. Mood, appetite for risk, alcohol tolerance, even how food tastes. The body keeps score in unexpected columns.
One thing to do: if you're on a GLP-1, keep a simple weekly note — not a food diary, just two or three sentences about how your body feels and what you're drawn to. Pattern recognition, done quietly, is often where the real information lives.
